Arctic Aurora LifeScience H |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 2.8 | 10.0 | -7.6 | 1.5 | 4.3 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 03/05/2024 | NOK 1891.90 | |
Day Change | 1.35% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00BDHFW354 | |
Fund Size (Mil) 31/03/2024 | NOK 2529.21 | |
Share Class Size (Mil) 31/03/2024 | NOK 167.93 | |
Max Initial Charge | - | |
Ongoing Charge 29/12/2023 | 1.16% |
Investment Objective: Arctic Aurora LifeScience H |
The investment objective is to achieve long-term capital appreciation through global equity investments within the pharmaceuticals, biotechnology and life science sectors. The team has more than 50 years of experience from the industry, and will utilize their know-how to pick the early winners in a fast developing life science and biotech space. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ulrica Bjerke 27/05/2016 | ||
Daniel Bolanowski 01/06/2021 | ||
Inception Date 30/06/2016 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Pharma Bio&Life NR NOK | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Arctic Aurora LifeScience H | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.76 |
AstraZeneca PLC | Healthcare | 5.35 |
Novo Nordisk A/S Class B | Healthcare | 5.20 |
Merck & Co Inc | Healthcare | 4.40 |
Novartis AG Registered Shares | Healthcare | 3.45 |
Increase Decrease New since last portfolio | ||
Arctic Aurora LifeScience H |